SCHEMBL5103229

SCHEMBL5103229

CCOC(=O)C(C)(C)Oc1ccc(OCCc2nc(-c3cccc(-c4ccccc4)c3)oc2C)cc1CCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 19/20 0.58
PPARG P37231 17/20 0.58
PPARD Q03181 6/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5103209 0.95 PPARA (0.60) PPARAPPARGPPARD
SCHEMBL5111519 0.95 PPARG (0.59) PPARAPPARGPPARD
SCHEMBL6695453 0.92 PPARA (0.65) PPARAPPARGPPARD
SCHEMBL5105604 0.90 PPARG (0.56) PPARAPPARGPPARD
SCHEMBL6699062 0.89 PPARA (0.60) PPARAPPARGPPARD
SCHEMBL5104777 0.89 PPARG (0.59) PPARAPPARGPPARD
SCHEMBL5105999 0.89 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL6695570 0.89 PPARA (0.62) PPARAPPARGPPARD
SCHEMBL5102578 0.89 PPARA (0.61) PPARAPPARGPPARD
SCHEMBL5106454 0.89 PPARA (0.63) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS BROOKS DAWN ALISA 2008-06-19 US disclosed
US-7351728-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2008-04-01 US disclosed
EP-1313715-B1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-08-01 EP disclosed
US-6982278-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY (US) 2006-01-03 US disclosed
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists BROOKS DAWN A 2005-11-10 US disclosed
US-6825222-B2 2-(4-(2-(2-BIPHENYL-YL-5-METHYL-THIAZOL-4-YL)-ALKOXY)-PHENOXY) -2-METHYL-PROPIONIC ACID DERIVATIVES; ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2004-11-30 US disclosed
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists BROOKS DAWN ALISA (US) 2004-02-05 US disclosed
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents ELI LILLY & COMPANY 2004-01-29 US disclosed
EP-1206457-B1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS LILLY CO ELI (US) 2003-10-15 EP disclosed
US-6610696-B2 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) ELI LILLY AND COMPANY 2003-08-26 US disclosed
EP-1313715-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
US-20030045558-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY & COMPANY LILY CORPORATE CENTER (US) 2003-03-06 US disclosed
WO-2001016120-A9 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS LILLY CO ELI (US) 2002-07-11 WO disclosed
US-6417212-B1 PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS ELI LILLY & COMPANY 2002-07-09 US disclosed
EP-1206457-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2002-05-22 EP disclosed
WO-2002018355-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-03-07 WO disclosed
WO-2001016120-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents SLC5A2, SLC5A1, GLP1R PPARA 19/4885PPARG 26/4885PPARD 68/4885
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20030045558-A1 Modulators of peroxisome proliferator activated receptors PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.